Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
PDX1328 Ceritinib
1.0
ALK
RTK
 -0.0229 0.06776
PDX1328 Ceritinib
3.1623
ALK
RTK
 -0.4675 0.22165
MCF7 Tivantinib
0.31623
MET
RTK
 0.2140 0.11704
PDX1328 Neratinib
0.0031623
EGFR/HER2
RTK
 0.7975 0.01498
PDX1328 Neratinib
0.031623
EGFR/HER2
RTK
 0.7149 0.01312
PDX1328 Neratinib
0.1
EGFR/HER2
RTK
 0.5651 0.01085
MCF7 Tivantinib
0.1
MET
RTK
 0.6729 0.02472
PDX1328 Neratinib
3.1623
EGFR/HER2
RTK
 -0.4202 0.24569
PDX1328 Tivantinib
0.0031623
MET
RTK
 1.1499 0.00008
PDX1328 Tivantinib
0.01
MET
RTK
 1.1030 -0.00125
HCC1806 Ceritinib
0.0031623
ALK
RTK
 1.0658 -0.00214
MCF 10A Ceritinib
0.1
ALK
RTK
 0.9635 -0.00161
MCF 10A Cediranib
0.31623
VEGFR/cKIT
RTK
 1.0087 -0.00055
MCF7 Cediranib
0.0031623
VEGFR/cKIT
RTK
 1.0519 -0.00143
MCF7 Cediranib
0.1
VEGFR/cKIT
RTK
 1.0382 -0.00225
MCF7 Cediranib
0.31623
VEGFR/cKIT
RTK
 0.9975 0.00032
MCF7 Cediranib
3.1623
VEGFR/cKIT
RTK
 0.7736 0.00746
MCF7 Cediranib
10.0
VEGFR/cKIT
RTK
 0.1149 0.16822
MCF7 Cabozantinib
0.031623
VEGFR2/MET
RTK
 1.0228 0.00136
MCF7 Cabozantinib
0.1
VEGFR2/MET
RTK
 0.9964 0.00101
MCF7 Cabozantinib
1.0
VEGFR2/MET
RTK
 0.9636 0.00456
MCF7 Cabozantinib
3.1623
VEGFR2/MET
RTK
 0.7384 0.01503
HCC1806 Ceritinib
0.001
ALK
RTK
 1.0121 0.00605
PDX1328 Cediranib
0.01
VEGFR/cKIT
RTK
 0.9326 0.00627
PDX1328 Cediranib
0.0031623
VEGFR/cKIT
RTK
 0.9678 0.00748